CANY
AVEO

Caxton Associates (New York)’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Caxton Associates (New York)’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-117,452
Closed -$1.76M – 683
2022
Q4 		$1.76M Buy
117,452
+3,291
+3% +$45.6K 0.12% 54
2022
Q3 		$940K Buy
+114,161
New +$877K 0.13% 131

Caxton Associates (New York)'s AVEO Position: Q1 2023 in Review

Caxton Associates (New York) sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 117,452 shares — an estimated $1.76M sold.

Caxton Associates (New York) first reported a position in AVEO in Q3 2022 and held it in 2 quarters. The position peaked at $1.76M in Q4 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.

  • Caxton Associates (New York) reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 117,452 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $1.76M.
  • Caxton Associates (New York) first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2022 and held it in 2 quarters.
  • Caxton Associates (New York)'s AVEO Pharmaceuticals, Inc. position peaked at $1.76M in Q4 2022.
  • 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.

Based on Caxton Associates (New York)'s 13F filing for Q1 2023, filed 15 May 2023.